CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies

Download All
In this engaging online program, watch experts discuss emerging strategies and current best practices in CAR T-cell therapy for patients with lymphomas, leukemias, and myelomas. Download slides with all the key data, view the on-demand Webcast, and join the discussion with expert-authored commentaries and podcasts.
Jeremy S. Abramson, MD, MMSc

ClinicalThought

With the approval of lisocabtagene maraleucel, another CAR T-cell therapy option is now available for patients with relapsed/refractory lymphomas. Review this expert commentary on how to incorporate this agent into your practice.

Jeremy S. Abramson, MD, MMSc Released: March 12, 2021
Provided by Medical College of Wisconsin in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Kite Pharma

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings